Aprepitant is classified being an NK1 antagonist mainly because it blocks signals specified off by NK1 receptors. This, thus, decreases the likelihood of vomiting in patients. Demo investigators presented information on loss to follow‐up by intervention at 3‐year follow‐up (electronic mail conversation) Hazard of bias summary: evaluation authors' judgements about https://mg-13222198.ja-blog.com/26951101/the-smart-trick-of-lanepitant-that-nobody-is-discussing